Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Pipeline Review, H2 2016

  • ID: 4035465
  • Drug Pipelines
  • Region: CIS
  • 46 pages
  • Global Markets Direct
1 of 5
Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Pipeline Review, H2 2016

Summary

‘Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Pipeline Review, H2 2016’, provides in depth analysis on Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted pipeline therapeutics.

The report provides comprehensive information on the Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted therapeutics development and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
Certain sections in the report may be removed or altered based on the availability and relevance of data.
Updated report will be delivered in 48 hours of order confirmation.

Scope:

- The report provides a snapshot of the global therapeutic landscape for Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8)
- The report reviews Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted therapeutics and enlists all their major and minor projects
- The report assesses Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted therapeutics

Reasons to Buy:

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Introduction

Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) Overview

Therapeutics Development

Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Products under Development by Stage of Development

Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Products under Development by Therapy Area

Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Products under Development by Indication

Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Pipeline Products Glance

Early Stage Products

Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Products under Development by Companies

Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Companies Involved in Therapeutics Development

ContraVir Pharmaceuticals Inc

Cypralis Ltd

Debiopharm International SA

Enanta Pharmaceuticals Inc

Ensemble Therapeutics Corp

Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Drug Profiles

alisporivir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alisporivir + EDP-239 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRV-431 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cyclophilin A for Hepatitis B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cyclophilin A for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Dormant Projects

Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Discontinued Products

Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Featured News & Press Releases

Dec 08, 2016: ContraVirs Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway in Hepatitis B

Sep 12, 2016: ContraVir Reports New CRV431 Data Highlighting Synergistic Activity with CMX157 Against Hepatitis B

Aug 22, 2016: ContraVir to Release New CRV431 Data Highlighting Potential Synergy with CMX157 Against Hepatitis B

Apr 19, 2016: Ciclofilin Pharmaceuticals Invited to Present Hepatitis B Drug Data at Cambridge Healthtech Institute’s Eleventh Annual Drug Discovery Chemistry Conference

Feb 04, 2016: Ciclofilin Pharmaceuticals Welcomes Dr. Nikolai Naoumov to Its Scientific Advisory Board

Dec 02, 2015: Ciclofilin Pharmaceuticals Announces Formation of World-Class HBV and Liver Disease Scientific Advisory Board

Nov 30, 2015: Ciclofilin Pharmaceuticals to Present at HEP DART 2015

Sep 08, 2015: Debiopharm International and Solid Biosciences Announce a Collaboration to Explore the Use of Alisporivir in Muscular Dystrophy

Aug 04, 2015: Ciclofilin Pharmaceuticals Receives Notice of Patent Allowance for Novel Cyclophilin Inhibitor

Jul 28, 2015: Ciclofilin Pharmaceuticals' Lead Antiviral Drug Reduces Liver HBV DNA

Jun 24, 2015: Ciclofilin Pharmaceuticals' HBV Drug Demonstrates Anti-Fibrotic Activity

Feb 24, 2015: Ciclofilin Pharmaceuticals Granted Patent in Japan for Cyclophilin Inhibitor Drugs

Feb 17, 2015: Ciclofilin Pharmaceuticals to Present HBV/HIV/HCV Co-Infection Results at EASL 2015

Nov 13, 2014: The Government of Canada Provides Support to Ciclofilin Pharmaceuticals for the Pre-Clinical Development of Its Lead Drug

Nov 04, 2014: Ciclofilin Pharmaceuticals to Present HIV/HCV Co-Infection Results at AASLD in Boston on November 11

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by ContraVir Pharmaceuticals Inc, H2 2016

Pipeline by Cypralis Ltd, H2 2016

Pipeline by Debiopharm International SA, H2 2016

Pipeline by Enanta Pharmaceuticals Inc, H2 2016

Pipeline by Ensemble Therapeutics Corp, H2 2016

Dormant Projects, H2 2016

Discontinued Products, H2 2016

List of Figures:

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • ContraVir Pharmaceuticals Inc
  • Cypralis Ltd
  • Debiopharm International SA
  • Enanta Pharmaceuticals Inc
  • Ensemble Therapeutics Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll